MDG2 Stock Financial Analysis - Medigene AG (WBAG) Stock

Overview

Medigene AG is a biotechnology firm based in Germany, primarily engaged in the development of immunotherapies for the treatment of cancer. The company leverages cutting-edge research to advance its expertise in T cell-receptor (TCR) therapies, aiming to develop treatments that can specifically target and combat tumorous cells in a highly effective manner. Key projects include TCR-based therapies in clinical trials, designed to enhance the immune system's ability to recognize and destroy cancer cells with high precision. Medigene’s strategic focus is not only on the development but also on the commercialization of its therapies, looking to fill critical gaps in available cancer treatments and improve patient outcomes in the oncology sector.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Medigene AG as of 30 June 2024 is 7.45 MM.
The operating income for Medigene AG as of 30 June 2024 is -15.42 MM.
The net income for Medigene AG as of 30 June 2024 is -15.93 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-06-30	7.45	-15.42	-15.93
2024-03-31	6.74	-15.78	-16.05
2023-12-31	6.03	-16.15	-16.18
2023-09-30	7.53	-13.24	-22.70
2023-06-30	9.03	-10.33	-29.22
2023-03-31	20.14	0.69	-18.77
2022-12-31	31.25	11.71	-8.33
2022-09-30	31.35	11.78	0.64
2022-06-30	31.46	11.86	9.60
2022-03-31	20.96	1.77	-0.19
2021-12-31	10.46	-8.32	-9.98
2021-09-30	9.54	-14.23	-15.99
2021-06-30	8.62	-20.15	-22.01
2021-03-31	8.31	-23.67	-25.44
2020-12-31	8.00	-27.20	-28.88
2020-09-30	9.43	-24.32	-25.35
2020-06-30
2020-03-31

Income Statement: EPS

The earnings per share basic for Medigene AG as of 30 June 2024 is -1.26.
The earnings per share diluted for Medigene AG as of 30 June 2024 is -1.26.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-06-30	-1.26	-1.26
2024-03-31	-1.29	-1.29
2023-12-31	-1.32
2023-09-30	-1.85	-1.85
2023-06-30	-2.38	-2.38
2023-03-31	-1.53	-1.53
2022-12-31	-0.68
2022-09-30	0.05	0.05
2022-06-30	0.78	0.78
2022-03-31	-0.02	-0.02
2021-12-31	-0.81
2021-09-30	-1.30	-1.30
2021-06-30	-1.79	-1.79
2021-03-31	-2.07	-2.07
2020-12-31	-2.35
2020-09-30	-2.06	-2.06
2020-06-30	-1.86	-1.86
2020-03-31	-1.67	-1.67

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Medigene AG as of 30 June 2024 is -14.17 MM.
The cash from investing activities for Medigene AG as of 30 June 2024 is 7.53 MM.
The cash from financing activities for Medigene AG as of 30 June 2024 is 4.11 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-06-30	-14.17	7.53	4.11
2024-03-31	-14.65	4.96	1.67
2023-12-31	-15.12	2.38	-0.78
2023-09-30	-14.24	2.08	-0.48
2023-06-30	-13.36	1.78	-0.19
2023-03-31	-0.69	-5.11	-0.23
2022-12-31	11.98	-12.01	-0.28
2022-09-30	12.95	-9.61	-0.54
2022-06-30	13.93	-7.21	-0.81
2022-03-31	1.59	-1.59	-0.92
2021-12-31	-10.75	4.03	-1.03
2021-09-30	-13.79	12.03	-0.89
2021-06-30	-16.82	20.03	-0.75
2021-03-31	-20.80	20.57	-0.79
2020-12-31	-24.79	21.12	-0.83
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Medigene AG as of 30 June 2024 is -0.31.
The roe for Medigene AG as of 30 June 2024 is -0.43.
The roic for Medigene AG as of 30 June 2024 is -0.67.
The croic for Medigene AG as of 30 June 2024 is -0.33.
The ocroic for Medigene AG as of 30 June 2024 is -0.61.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2024-06-30	-0.31	-0.43	-0.67	-0.33	-0.61
2024-03-31	-0.31	-0.44	-0.67	-0.56	-0.63
2023-12-31	-0.44	-0.61	-0.95	-0.53	-0.59
2023-09-30	-0.38	-0.49	-0.87	-0.35	-0.40
2023-06-30	-0.38	-0.49	-0.87	-0.35	-0.40
2023-03-31	-0.32	-0.42	-0.46	-0.15	-0.02
2022-12-31	0.01	0.01	0.02	0.07	0.32
2022-09-30	0.01	0.01	0.02	0.07	0.32
2022-06-30	0.14	0.19	0.15	0.10	0.22
2022-03-31	-0.00	-0.00	-0.00	-0.01	0.03
2021-12-31	-0.13	-0.19	-0.20	-0.16	-0.22
2021-09-30	-0.21	-0.30	-0.33	-0.05	-0.28
2021-06-30	-0.24	-0.32	-0.41	0.04	-0.31
2021-03-31	-0.23	-0.31	-0.44	-0.02	-0.36
2020-12-31	-0.26	-0.35	-0.50	-0.08	-0.43
2020-09-30	-0.22	-0.30	-0.43	-0.06	-0.46
2020-06-30	-0.19	-0.25	-0.31	-0.05	-0.36
2020-03-31	-0.16	-0.20	-0.24	0.08	-0.19

Gross Margins

The gross margin for Medigene AG as of 30 June 2024 is 0.77.
The net margin for Medigene AG as of 30 June 2024 is -2.38.
The operating margin for Medigene AG as of 30 June 2024 is -2.34.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2024-06-30	0.77	-2.38	-2.34
2024-03-31	0.73	-2.68	-2.68
2023-12-31	0.75	-3.01	-1.76
2023-09-30	0.77	-3.24	-1.15
2023-06-30	0.77	-3.24	-1.15
2023-03-31	0.90	-0.93	0.03
2022-12-31	0.94	0.02	0.38
2022-09-30	0.94	0.02	0.38
2022-06-30	0.95	0.31	0.32
2022-03-31	0.93	-0.01	0.00
2021-12-31	0.87	-0.95	-0.96
2021-09-30	0.83	-1.68	-1.58
2021-06-30	0.78	-2.55	-2.34
2021-03-31	0.81	-3.06	-2.85
2020-12-31	0.84	-3.61	-3.40
2020-09-30	0.93	-2.69	-2.58
2020-06-30	1.00	-2.67	-2.68
2020-03-31	1.00	-2.00	-2.03